These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17000334)

  • 1. Medical management of advanced Parkinson's disease.
    Goudreau JL
    Clin Geriatr Med; 2006 Nov; 22(4):753-72, v. PubMed ID: 17000334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK; Cordato DJ; O'Rourke F
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Olanow CW; Jankovic J
    Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R; Ling H
    J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care.
    Chen JJ
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S322-7. PubMed ID: 22087553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subthalamic nucleus stimulation in Parkinson's disease patients intolerant to levodopa.
    Lyons KE; Davis JT; Pahwa R
    Stereotact Funct Neurosurg; 2007; 85(4):169-74. PubMed ID: 17259749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced Parkinson's disease.
    Diamond A; Jankovic J
    Expert Rev Neurother; 2006 Aug; 6(8):1181-97. PubMed ID: 16893346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A young onset Parkinson's patient: a case study.
    Jung SK
    J Neurosci Nurs; 2004 Oct; 36(5):273-7. PubMed ID: 15524245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
    Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
    Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
    Devos D;
    Mov Disord; 2009 May; 24(7):993-1000. PubMed ID: 19253412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.